华法林相关颅内出血中凝血酶原复合物的给药时机
该研究为回顾性、观察性、单中心研究,在大社区教学医院开展,评估4因子凝血酶原复合物(4F-PCC)给药时间与华法林相关颅内出血有效止血(影像科医师估计血肿体积增加≤20%)的关系。227例患者筛查后39例纳入,按CT诊断颅内出血至4F-PCC给药时间分为<45分钟、45-90分钟、>90分钟三组。主要结局在三组间无显著差异(85.7% vs 73.3% vs 90%,p值0.514)。院内死亡率、住院时长和ICU时长等次要结局组间亦无差异。结论认为本研究未发现4F-PCC给药时间与以血肿扩大≤20%定义的有效止血率存在关联。
要点
- 按CT诊断颅内出血至4F-PCC给药时间分组:<45分钟组有效止血率85.7%,45-90分钟组73.3%,>90分钟组90%,组间p值0.514。
- 院内死亡率、住院时长、ICU时长等次要结局在三组间均无差异。
- 研究共筛查227例,最终纳入39例,基线特征组间相似。
- 指南推荐对华法林相关颅内出血「快速」和「紧急」逆转抗凝,但未明确给药时间目标。
适用人群与场景
- 华法林相关颅内出血患者,在大型社区教学医院接受4F-PCC治疗。
诊断标准与关键阈值
- 有效止血定义为影像科医师估计的血肿体积增加≤20%。
- 按CT诊断颅内出血至4F-PCC给药时间分为<45分钟、45-90分钟和>90分钟三组。
研究设计与关键结果
- 研究类型:回顾性、观察性、单中心研究,在大型社区教学医院开展。
- 样本量:筛查227例,最终纳入39例。
- 主要结局:有效止血率在<45分钟组、45-90分钟组和>90分钟组分别为85.7% vs 73.3% vs 90%,p值0.514,组间无显著差异。
- 次要结局:院内死亡率、住院时长和ICU时长组间均无差异。
- 基线特征组间相似。
证据类型、等级与局限
- 证据类型:回顾性、观察性、单中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 本研究未发现4F-PCC给药时间与以血肿扩大≤20%定义的有效止血率存在关联,院内死亡率、住院时长和ICU时长组间亦无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Guidelines recommend "rapid" and "urgent" reversal of anticoagulation for warfarin-associated intracranial hemorrhage (ICH) treatment; however, they do not specify goals for time-to-administration. There are limited studies evaluating time to reversal, or international normalized ratio (INR) correction, on hematoma expansion and outcomes in intervals of <4 h. The purpose of this study was to evaluate the association of 4-factor prothrombin concentrate (4F-PCC) time-to-administration on rates of achieving effective hemostasis, determined by hematoma expansion, for treatment of warfarin-associated ICH.
METHODS: This was a retrospective, observational, single center study performed at a large community teaching hospital. Patients were stratified into three groups based on time of CT diagnosis of ICH to administration of 4F-PCC: <45 min, 45-90 min, and >90 min. The primary outcome was rates of achieving effective hemostasis in each group defined as a ≤20% increase in hematoma volume as estimated by a radiologist.
RESULTS: A total of 227 patients were screened for inclusion with ultimately 39 being included. Baseline characteristics were similar between groups. The primary outcome was not significantly different among groups stratified by time to 4F-PCC administration of <45 min, 45-90 min, and >90 min (85.7% vs 73.3% vs 90%, p value 0.514). There was no difference among secondary outcomes between groups including in-hospital mortality, hospital length of stay (LOS), and intensive care unit LOS.
CONCLUSION: There was no association with time-to-administration of 4F-PCC on rates of hemostasis achievement, defined as hematoma expansion of ≤20%, identified in this study.
参考来源
- Townsend B, Slechta J, Gilbert BW, et al. Prothrombin complex concentrate administration timing in warfarin-associated intracranial hemorrhage. Am J Emerg Med. 2023. PMID: 38071882. doi:10.1016/j.ajem.2023.11.040
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。